TickerFacts.

Jade Biosciences, Inc. (JBIO): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$94.69M
Year ended 2025-12-31
-$123.51M
Trailing 12 months to 2026-06-30
2020-12-31: -$7.86M2021-12-31: -$27.40M2022-12-31: -$39.12M2023-12-31: -$56.78M2024-12-31: -$71.20M2025-12-31: -$94.69M-$94.69M
2020-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$94.69Mn/m2026-03-06, From 2025-01-01
2024-12-31-$71.20Mn/m2025-03-27, From 2024-01-01
2023-12-31-$56.78Mn/m2025-03-27, From 2023-01-01
2022-12-31-$39.12Mn/m2024-03-25, From 2022-01-01
2021-12-31-$27.40Mn/m2023-03-29, From 2021-01-01
2020-12-31-$7.86Mn/a2022-03-30, From 2020-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Jade Biosciences, Inc. (JBIO)2025-12-31-$94.69Mn/m
Zymeworks Inc. (ZYME)2025-12-31-$33.01Mn/m
Upstream Bio, Inc. (UPB)2025-12-31-$133.28Mn/m
Capricor Therapeutics, Inc. (CAPR)2025-12-31-$69.81Mn/m
Lyell Immunopharma, Inc. (LYEL)2025-12-31-$150.02Mn/m
Keros Therapeutics, Inc. (KROS)2025-12-31$107.50Mn/m
Anaptysbio, Inc (ANAB)2025-12-31$19.70Mn/m
Fulcrum Therapeutics, Inc. (FULC)2025-12-31-$60.06Mn/m
ArriVent BioPharma, Inc. (AVBP)2025-12-31-$160.59Mn/m

Compare JBIO, ZYME, UPB, CAPR side by side · Screen every company in Pharmaceutical Preparations ↗